Journal article icon

Journal article

Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective.

Abstract:

INTRODUCTION: Previous research has demonstrated that tenofovir disoproxil fumarate (DF) is the most cost-effective nucleos(t)ide treatment for chronic hepatitis B (CHB) in the UK, Spain, Italy and France. However, to our knowledge, no published studies have yet evaluated the cost effectiveness of any treatments for CHB in a Canadian setting, where relative prices and management of CHB differ from those in Europe. AIM: Our objective was to determine the cost effectiveness of tenofovir DF comp...

Expand abstract

Actions


Access Document


Authors


Sherman, M More by this author
Bentley, A More by this author
Journal:
Pharmacoeconomics
Publication date:
2011-10-14
DOI:
EISSN:
1179-2027
URN:
uuid:bb479ac5-6ccf-4944-8f02-6b3fdbf43772
Source identifiers:
252465
Local pid:
pubs:252465
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP